Document is current
Any future updates will be listed below
-
Authors
Okada, Annabelle A. https://orcid.org/0000-0002-8850-8962
Takahashi, Kanji
Ohji, Masahito
Moon, SungChul Charles
Machewitz, Tobias
Sasaki, Koji
,
Ohji, Masahito
Hanemoto, Tsukasa
Kaga, Tatsushi
Kouno, Takeya
Kitamei, Hirokuni
Sato, Shinpei
Takahashi, Kanji
Yanai, Ryoji
Uchio, Eiichi
Miyata, Kazunori
Wakabayashi, Yoshihiro
Maeno, Takatoshi
Yasukawa, Tsutomu
Horiguchi, Masayuki
Nishimura, Tetsuya
Kawahara, Akiteru
Kurimoto, Yasuo
Murai, Kenichi
Kobayashi, Namie
Kimura, Wataru
Matsushita, Eriko
Iida, Tomohiro
Yasuda, Kanako
Miura, Masahiro
Okada, Annabelle Ayame
Mori, Ryusaburo
Sugiyama, Atsushi
Ito, Yasuo
Kimura, Daisaku
Nakai, Kei
Matsumoto, Chota
Takeuchi, Shinobu
Okoshi, Kishiko
Nuno, Yoshihisa
Nomoto, Yohei
Mori, Toshio
Takeda, Muneyasu
Yoshida, Noriko
Hosokawa, Mio
Sonoda, Kohei
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02305238 at ClinicalTrials.govDocuments that mention this clinical trial
Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in the ALTAIR Study: 96-Week Outcomes in the Polypoidal Choroidal Vasculopathy Subgroup
https://doi.org/10.1007/s12325-022-02162-w
-
Funding
Funding for this research was provided by:
Bayer Consumer Care AG
- License Information
-
More Information
Article History
Received: 10 February 2022
Accepted: 8 April 2022
First Online: 3 May 2022
